Editing Clinical Trials (section)

=== TNhYP218 Trial at National Cancer Institute (NCT06885697) ===

This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.

'''Trial Details:'''
* '''Status:''' Recruiting since 2025
* '''Location:''' National Cancer Institute, Bethesda, Maryland
* '''Innovation:''' Targets membrane-proximal epitope of mesothelin, showing 2-4 fold better tumor killing than membrane-distal approaches in preclinical studies
* '''Eligibility:''' Age 18 or older, mesothelin expression greater than 50% of tumor cells, ECOG 0-1
* '''Monitoring:''' Patients must remain within 2 hours of NIH for 30 days post-infusion
* '''Follow-up:''' 15 years per FDA requirement